¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
º¸°í¼ ¸ÞŸµ¥ÀÌÅÍ
- Áö¿ªÀû ¹üÀ§ : À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´ Àü¿ª)
- ¸ð´Þ¸®Æ¼ : CT, MRI, X¼±/DR, ÃÊÀ½ÆÄ, PET/ÇÙÀÇÇÐ
- ÀÓ»ó ºÐ¾ß : Á¾¾çÇÐ, ½Å°æÇÐ/³úÁ¹Áß, ½ÉÀ庴ÇÐ, È£Èí±â/Æó, MSK/Á¤Çü, ÀÏ¹Ý Áø´Ü
- ¿ëµµ : Á¶±â ¹ß°ß/Æ®¸®¾ÆÁö, Áø´Ü Á¤µµ¿Í ºÐ·ù, ¿öÅ©Ç÷οì/È¿À², ¿¹ÈÄ¿Í Ä¡·á, ¿µ»ó °Á¶/¼±·®, ¼¼ºÐÈ/Ư¡ ÃßÃâ, ¸ð´Þ¸®Æ¼ °£ ÅëÇÕ
- ¸ÅÃâ È帧 : Çϵå¿þ¾î(°øÀå ÃâÇϽà CAPEX »óÇâ Á¶Á¤), ¼ÒÇÁÆ®¿þ¾î(±â¾÷¿ë ±¸µ¶À» Æ÷ÇÔÇÑ °íÁ¤ ¶óÀ̼±½º), ¼ºñ½º(µµÀÔ/°ËÁõ/Áö¿ø), Ŭ¶ó¿ìµå/»ç¿ë·® ±â¹Ý(½ºÄµ´ç Á¾·®Á¦)
- ÃÖÁ¾ ¿ëµµ : º´¿ø, ¿µ»ó Áø´Ü ¼¾ÅÍ, Ŭ¸®´Ð, ¿ø°Ý¹æ»ç¼±Áø´Ü, ±âŸ ÇÁ·Î¹ÙÀÌ´õ
º¸°í¼ ¿ä¾à
À¯·´ÀÇ AI Áö¿ø ÀÇ·á ¿µ»ó ½ÃÀå : 2025³â º¸°í¼´Â µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´ ±¹°¡ÀÇ CT, MRI, X-ray/DR, ÃÊÀ½ÆÄ, PET/ÇÙÀÇÇÐ ºÐ¾ßÀÇ AI ÁöÃâÀ» ÃøÁ¤ ¹× ¿¹ÃøÇß½À´Ï´Ù. 2023-2024³â ½ÇÀû°ú2025-2032³â ¿¹ÃøÀ»¸ð´Þ¸®Æ¼º°, ÀÓ»óºÐ¾ßº°, ¿ëµµº°, ¼öÀÔ¿øº°, ÃÖÁ¾ »ç¿ë Á¶Á÷º°, AI ±â¼úº°, ±×¸®°í À¯·´¿¡ ¸ÂÃá GTM ¼ºÀå-¼º¼÷µµ, »ýÅÂ°è ¿¬°è ¼Ö·ç¼Ç µµÀÔ ¹× ¼ºÀå ÇÁ·¹ÀÓ¿öÅ©º°·Î °Ô½ÃÇϰí ÀÖ½À´Ï´Ù.
ÀÌ Marketstrat(TMÀÇ 88ÆäÀÌÁö¿¡ °ÉÄ£ Markintel(TM)Pulse ÀÌ º¸°í¼´Â ÀÇ·á¿ë ¿µ»óó¸® ºÐ¾ßÀÇ AI¿¡ ´ëÇÑ À¯·´¸¸À» ´ë»óÀ¸·Î ÇÕ´Ï´Ù. Áö¿ªº° ÇÁ·¹ÀÓ¿öÅ©-GTM ¼ºÀå°ú ¼º¼÷µµ(º¥´õ ºä),»ýŰè Çù¾÷ ¸ÅÆ®¸¯½º,¼Ö·ç¼Ç äÅðú ¼ºÀå-´Â Áõ°Å¸¦ ½ÃÄö½Ì, Á¦ÈÞ, °¡°Ý °áÁ¤À¸·Î º¯È¯ÇÕ´Ï´Ù. µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´ ±¹°¡ ±¹°¡º° Àå¿¡¼´Â GTMÀÇ Áغñ »óȲ, °¡°Ý Ã¥Á¤ ÀûÇÕ¼º, °èÃþÈµÈ °í°´ »óȲ µîÀ» ¼ö·ÏÇß½À´Ï´Ù. Á¶»ç ¹æ¹ýÀ¸·Î´Â À¯·´ÀÇ ÇÏÇâ½Ä ÁöÃ⠸𵨺°, ¾ç½Äº°, ±¹°¡º°, Áö¿ªº° »óÇâ½Ä ÀåÂø·ü ¡¿ ASP ¿£Áø Á¶Á¤, ±ÔÁ¦ ´ç±¹¿¡ Á¦ÃâÇÑ ¼·ù, °¨»ç¹ÞÀº À繫 Á¤º¸, ¸éÇ㸦 ÃëµæÇÑ Àü¹®°¡ÀÇ °¿¬ ±â·Ï, RWE¿¡ ÀÇÇØ °¡ÁßÄ¡¸¦ ºÎ¿©ÇÕ´Ï´Ù.
°¢±¹ÀÇ Çö½Ç: µ¶ÀÏÀº 2027³â±îÁö ¸ðµâÇü SaaS·Î Àüȯ, ¿µ±¹Àº Ŭ¶ó¿ìµå/ÀÌ¿ë °¡°Ý Áß½Ã, ÇÁ¶û½º´Â ÅëÇÕ°ú ÄÄÇöóÀ̾𽺠¿ì¼±, ÀÌÅ»¸®¾Æ´Â PNRRÀ» ÅëÇØ MR ÁÖµµ AI ¼ºÀå, ½ºÆäÀÎ »ç·Ê´Â ¹é·Î±× °¨¼Ò, RoE Ŭ·¯½ºÅÍ´Â °·ÂÇÑ ¸®Æ®·ÎÇÍ °¡´É¼º¸¦ º¸¿©ÁÝ´Ï´Ù.
ÀÇ»ç°áÁ¤À» À§ÇÑ ÇÁ·¹ÀÓ¿öÅ© GTMÀÇ ¼ºÀå°ú ¼º¼÷µµ, »ýŰè Çù¾÷, ¼Ö·ç¼Ç äÅðú ¼ºÀå - ¸ðµÎ À¯·´ ¼öÁØ.
ÀÌ º¸°í¼ÀÇ ´ë»óÀÚ
- OEM ¸®´õ½Ê(Á¦Ç°,Áö¿ªGM,Àü·«)
- AI Àü¹® º¥´õ & Ç÷§Æû(â¾÷ÀÚ, ¼¼ÀÏÁî ¸®´õ, ÆÄÆ®³Ê½Ê)
- °ø±ÞÀÚ ³×Æ®¿öÅ©(CIO/CMIO, ¹æ»ç¼±°ú À§¿øÀå, Á¶´Þ)
- ÅõÀÚÀÚ ¹× ÁÖ½Ä ºÐ¼®°¡(ÀÇ·á±â¼ú/HCIT)
- ÄÁ¼³ÆÃ & ÀÚ¹® ȸ»ç(GTM, ÇÁ¶óÀ̽Ì, µô¸®Àü½º)
¾î¶² ÀÇ»ç°áÁ¤À» Áö¿øÇÏ´ÂÁö(ÇöÀç/´ÙÀ½ ºÐ±â)
- ½ÃÀå¿¡¼ÀÇ »óÀå, ±â¾÷/Ç÷§Æû °Å·¡¸¦ À§ÇÑ »óÀå, ±â¾÷/Ç÷§Æû °Å·¡¸¦ À§ÇØ ¹øµé¸µÇÒ ¼Ö·ç¼Ç
- ±¹°¡º° °¡°Ý ¼³Á¤(±â°£Á¦)(±â¾÷¿ë ±¸µ¶Çü, ÀÌ¿ëÇü)
- Á¶´Þ ÄÉÀÌ´ø½º¿Í Áõ°Å¿¡ ´ëÇÑ ±â´ë¿¡ ¿¬µ¿µÈ ÆÄÀÏ·µ¿¡¼ ½ºÄÉÀÏ Ç÷£À¸·Î
- ±¹°¡º° ÆÄÆ®³Ê ·çÆ®(OEM ½ºÅä¾î, PACS ¸¶ÄÏÇ÷¹À̽º, Ŭ¶ó¿ìµå °Å·¡¼Ò)
³»¿ë
- À¯·´ÀÇ ÁÖ¿ä ¼öÄ¡: 2032³â±îÁöÀÇ ÃÑ¾× ¹× ¼ºÀå ¸¶ÀϽºÅæ
- ¸ð´Þ¸®Æ¼º°, ÀÓ»ó ¿µ¿ªº°, ¿ëµµº°, ¼öÀÔ¿øº°, ÃÖÁ¾ ¿ëµµº°, AI ±â¼úº°, AI ±â¼úº° ³»¿ª
- ±¹°¡º° éÅÍ(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´ Àü¿ª)
- GTM Áغñ ·¹ÀÌ´õ, ±¹°¡º° °¡°Ý ¸ÅÆ®¸¯½º, °èÃþº° °í°´ »óȲ, ¿¹ÃøÇ¥
- Áö¿ªº° ÇÁ·¹ÀÓ¿öÅ©(À¯·´ ¼öÁØ)
- GTMÀÇ ¼ºÀå°ú ¼º¼÷µµ - º¥´õ Áöµµ
- »ýÅÂ°è ¿¬°è ¸ÅÆ®¸¯½º(ECM)
- ¼Ö·ç¼Ç µµÀÔ ¹× ¼ºÀå ¸ÅÆ®¸¯½º
- Á¶»ç ¹æ¹ý: µà¾ó ·»Áî ¸ðµ¨(ÇÏÇâ½Ä Á¶Á¤, »óÇâ½Ä ÀåÂø·ü¡¿ASP), Áõ°Å °¡ÁßÄ¡ ºÎ¿©, QA Á¡°Ë
ÀÌ ÆÞ½º º¸°í¼¸¦ ±¸¸ÅÇØ¾ß ÇÏ´Â ÀÌÀ¯
- ÇϳªÀÇ ÀϰüµÈ ¸ðµ¨: ¸ð´Þ¸®Æ¼, ±¹°¡, ¿ëµµ, ¸ÅÃâ È帧À» °¡·ÎÁú·¯ ¼öÄ¡¸¦ Á¶Á¤ÇÕ´Ï´Ù.
- Áõ°ÅÀÇ °¡ÁßÄ¡ ºÎ¿©: ±ÔÁ¦, À繫, ÀÎÅͺ信 ±â¹ÝÇÑ ½Ã±×³ÎÀ» ¸íÈ®ÇÑ ½Å·Úµµ °¡ÁßÄ¡¿Í ÇÔ²² °áÇÕ
- Çൿ ÁöÇâÀû: ÇÁ·¹ÀÓ¿öÅ©°¡ µ¥ÀÌÅÍ ½ÃÄö½Ì Á¦ÈÞ, Á¦ÈÞ, °¡°Ý ¼³Á¤¿¡ ¹Ý¿µ
- Ä¿½ºÅÒ ½ºÅ͵𺸴٠´õ ºü¸£°Ô: À¯·´¿¡ ÁýÁßµÈ ½ºÄÚÇÁ, Áö±Ý ¹Ù·Î ÀÌ¿ë °¡´ÉÇÕ´Ï´Ù.
¹æ¹ý °³¿ä
- µà¾ó ·»Áî ¾ÆÅ°ÅØÃ³: ÇÏÇâ½Ä À¯·´ ÁöÃâ ¾ÞÄ¿ ÃѾװú »óÇâ½Ä °¢ ¾ç½Ä ¹× ±¹°¡º° ÷ºÎ ÆÄÀÏ ÀÛ¼º·ü ¡¿ ASP ¿£Áø ±Ô¸ð
- Áõ°ÅÀÇ ±âµÕ: CE MDR/UKCA ÆÄÀϸµ, °¨»ç¹ÞÀº À繫, ¸éÇ㸦 ÃëµæÇÑ Àü¹®°¡ÀÇ ÅëÈ ±â·Ï, µ¿·á °ËÅä ¶Ç´Â ÄÁÆÛ·±½º RWE
- QA: Ç¥/±×¸² °£ ¼öÄ¡ ÀÏÄ¡, ¹®¼ÈµÈ ¼Ò½º Æ®·¹ÀÏ, ¼¼ÄÁµå ¸®´õÀÇ ÆíÁý Á¡°Ë
¸ñÂ÷
¼½¼Ç 1 - °³¿ä
¼½¼Ç 2 - Á¶»ç ¹æ¹ý
- ÀÌ ÆÞ½º ¸®Æ÷Æ®¿¡ ´ëÇØ ¼Ò°³
- ½ºÄÚÇÁ¿Í ¼¼ºÐÈ
- MarketstratÀÇ "ÀλçÀÌÆ®¡æ¾×¼Ç" ¾îÇÁ·ÎÄ¡
- µà¾ó ·»Áî ¾ÆÅ°ÅØÃ³
- Åé´Ù¿îÇü ¸¶ÄÏ ÆÛ³Ú(À¯·´)
- º¸ÅÒ¾÷ Á¢¼Ó·ü Ç÷οì(À¯·´)
- °¢±¹ ¹× ºÎ¹®´ç ¸ðµ¨ÈÇÏ´Â ³»¿ë
- Áõ°Å ½Å·Ú¼º - ¹Ðµµ¿Í ½Å·Ú¼º(À¯·´)
- ÀÌ ÆÞ½º ¸®Æ÷Æ®¿¡ Æ÷ÇԵǴ Áö¿ª ÇÁ·¹ÀÓ¿öÅ©
- GTM ÄÁÆ®¸® Åø
- ǰÁú º¸Áõ°ú °Å¹ö³Í½º
- Á¦ÇѰú ¿ÏÈÃ¥
¼½¼Ç 3 - À¯·´ ½ÃÀå ºÐ¼®
- ½ÃÀå °³¿ä¿Í ºÐ¼®
- ½ÃÀå ½º³À¼ô
- ±¸Á¶ÀûÀÎ ¼ö¿ä ½Ã±×³Î
- ±ÔÁ¦¿Í ÀÚ±ÝÁ¶´Þ »óȲ(2024-2028³â)
- ½ÃÀå ¼¼ºÐÈ : 2032³â(°¡Ä¡ Á¡À¯À²)
- °æÀï È÷Æ®¸Ê(2024-2026³â)
- ½ÃÇà Ç÷¹À̺Ï(2024-2027³â)
- Çൿ ÁöÇâ ±ÇÀå»çÇ×
- À¯·´ ½ÃÀå Ã߻ꡤ¿¹Ãø(2023-2032³â, 100¸¸ ´Þ·¯)
- Markintel ¼ºÀå ¼º¼÷µµ ¸ÅÆ®¸¯½º - À¯·´
- Markintel ¿¡ÄڽýºÅÛ Çù¾÷ ¸ÅÆ®¸¯½º(ECM) - À¯·´
- Markintel ¼Ö·ç¼Ç µµÀÔ ¹× ¼ºÀå ¸ÅÆ®¸¯½º - À¯·´
- AI ¾îÅÂÄ¡À² - À¯·´
- GTM °³¿ä - À¯·´
¼½¼Ç 4 - µ¶ÀÏ ½ÃÀå
- ½ÃÀå °³¿ä - µ¶ÀÏ
- ¸ÅÅ©·Î¿Í ¿ªÇÐ
- ÀÇ·áÁ¦µµ¿Í ÀÚ±ÝÁ¶´Þ »óȲ
- ±ÔÁ¦¿Í Áõ°Å °æ·Î
- °æÀï ±¸µµ
- Àü·«Àû Æ÷ÀÎÆ®¿Í ±ÇÀå»çÇ×
- µ¶ÀÏ ½ÃÀå, ÀÓ»ó ºÐ¾ßº°
- µ¶ÀÏ ½ÃÀå, ¸ð´Þ¸®Æ¼º°(2023-2032³â, 100¸¸ ´Þ·¯)
- µ¶ÀÏ ½ÃÀå, ¼öÀÔ¿øº°(2023-2032³â, 100¸¸ ´Þ·¯)
- µ¶ÀÏ ½ÃÀå, ÀÓ»ó ÀÀ¿ëº°(2023-2032³â, 100¸¸ ´Þ·¯)
- µ¶ÀÏ ½ÃÀå, ÃÖÁ¾ ¿ëµµ Á¶Á÷º°(2023-2032³â, 100¸¸ ´Þ·¯)
- µ¶ÀÏ ½ÃÀå, AI ±â¼úº°(2023-2032³â, 100¸¸ ´Þ·¯)
- GTM °³¿ä - µ¶ÀÏ
¼½¼Ç 5 - ÇÁ¶û½º ½ÃÀå
- ½ÃÀå ¿ä¾à : ÇÁ¶û½º
- ÇÁ¶û½º ½ÃÀå Ã߻ꡤ¿¹Ãø(2023-2032³â)
- GTM °³¿ä - ÇÁ¶û½º
¼½¼Ç 6 - ¿µ±¹ ½ÃÀå
- ½ÃÀå °³¿ä - ¿µ±¹
- ¿µ±¹ ½ÃÀå
- ¿µ±¹ ½ÃÀå Ã߻ꡤ¿¹Ãø(2023-2032³â)
- GTM °³¿ä - ¿µ±¹
¼½¼Ç 7 - ÀÌÅ»¸®¾Æ ½ÃÀå
- ½ÃÀå °³¿ä¿Í ¿ä¾à : ÀÌÅ»¸®¾Æ
- ÀÌÅ»¸®¾Æ ½ÃÀå ¿¹Ãø(2023-2032³â)
- GTM °³¿ä - ÀÌÅ»¸®¾Æ
¼½¼Ç 8 - ½ºÆäÀÎ ½ÃÀå
- ½ÃÀå °³¿ä¿Í ¿ä¾à-½ºÆäÀÎ
- Àü·«Àû Æ÷ÀÎÆ®
- ½ºÆäÀÎ ½ÃÀå Ã߻ꡤ¿¹Ãø(2023-2032³â)
- GTM °³¿ä - ½ºÆäÀÎ
Á¦9Àå - ±âŸ À¯·´ ±¹°¡ ½ÃÀå
- ½ÃÀå °³¿ä : ±âŸ À¯·´ ±¹°¡
- Àü·«Àû Æ÷ÀÎÆ®
- À¯·´ÀÇ ÀÇ·á¿ë ¿µ»ó AI ½ÃÀå(2023-2032³â)
- GTM °³¿ä - ±âŸ À¯·´ ±¹°¡
KSA
Report Metadata
- Geographic scope: Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Modalities: CT, MRI, X ray/DR, Ultrasound, PET/Nuclear
- Clinical areas: Oncology, Neurology/Stroke, Cardiology, Respiratory/Lung, MSK/Ortho, General Diagnostic
- Applications: Early detection/triage; diagnostic accuracy & classification; workflow/efficiency; prognosis & treatment; image enhancement/dose; segmentation/feature extraction; integration across modalities
- Revenue streams: Hardware (factory attach CAPEX uplift), Software (fixed licenses incl. enterprise subscriptions), Service (implementation/validation/support), Cloud/Pay per Use (metered per scan)
- End use: Hospitals, Imaging Centers, Clinics, Teleradiology, Other providers
Report Summary
The Europe - AI assisted Medical Imaging Pulse report sizes and forecasts AI spend across CT, MRI, X ray/DR, Ultrasound, and PET/Nuclear for DE, FR, UK, IT, ES, RoE. It provides 2023-24 actuals and a 2025-2032 forecasts by modality, clinical area, application, revenue stream, end use organization, and AI technology-plus GTM Growth & Maturity, Ecosystem Collaboration, and Solution Adoption & Growth frameworks tailored to Europe.
This 88 page Markintel(TM) Pulse report from Marketstrat(TM) delivers a Europe only view of AI in medical imaging. Regional frameworks-GTM Growth & Maturity (vendor view), Ecosystem Collaboration Matrix, and Solution Adoption & Growth-translate evidence into sequencing, partnering, and pricing decisions. Country chapters for Germany, France, the UK, Italy, Spain, and RoE include GTM readiness, pricing fit, and tiered customer landscapes. Methodology reconciles a top down Europe spend model with bottom up attach rate x ASP engines by modality and country, weighted by regulatory filings, audited financials, licensed expert transcripts, and RWE.
Country reality: Germany pivots to modular SaaS by 2027; UK favors cloud/usage pricing; France prioritizes integration & compliance; Italy grows MR led AI via PNRR; Spain's case is backlog reduction; RoE clusters show strong retrofit potential.
Decision ready frameworks: GTM Growth & Maturity, Ecosystem Collaboration, Solution Adoption & Growth-all Europe level.
Who should use this report:
- OEM leadership (product, regional GMs, strategy)
- Specialist AI vendors & platforms (founders, sales leaders, partnerships)
- Provider networks (CIO/CMIO, radiology chairs, procurement)
- Investors & equity analysts (MedTech/HCIT)
- Consulting & advisory firms (GTM, pricing, diligence)
What decisions it supports (now/next quarter)
- Which solutions to bundle for enterprise/platform deals vs list in marketplaces.
- Pricing fit-term vs enterprise subscription vs usage based by country.
- Pilot to scale plans tied to procurement cadence and evidence expectations.
- Partner routes (OEM stores, PACS marketplaces, cloud exchanges) per country.
What's inside:
- Europe key numbers: totals and growth milestones through 2032.
- Breakdowns by modality, clinical area, application, revenue stream, end use, AI technology.
- Country chapters (DE, FR, UK, IT, ES, RoE) with: GTM readiness radar, country pricing matrix, tiered customer landscape, and forecast tables.
- Regional frameworks (Europe level):
- GTM Growth & Maturity - vendor map
- Ecosystem Collaboration Matrix (ECM)
- Solution Adoption & Growth Matrix
- Methodology: dual lens model (top down reconciliation; bottom up attach rate x ASP), evidence weighting, QA checks.
Why buy this Pulse report:
- One coherent model: numbers reconcile across modality, country, application, and revenue stream.
- Evidence weighted: regulatory, financial and interview based signals are combined with clear confidence weights.
- Action oriented: frameworks translate data into sequencing, partnering, and pricing moves.
- Faster than a custom study: focused Europe scope you can use today.
Methods in brief:
- Dual lens architecture: top down Europe spend anchors totals; bottom up attach rate x ASP engines size each modality and country.
- Evidence pillars: CE MDR/UKCA filings, audited financials, licensed expert call transcripts, and peer reviewed or conference RWE.
- QA: numeric parity across tables/figures; documented source trail; second reader editorial check.
TABLE OF CONTENTS
SECTION 1 - EXECUTIVE SUMMARY
- What this Pulse Covers
- Key Numbers Snapshot (Europe)
- What's Driving Europe's Curve
- Where the Value Pools Form
- Country Outlook-Six Different Routes to Scale
- Near term Watchlist (Next 12-18 Months)
- What to do now (Insights -> Action)
- OEMs
- Pure plays
- Providers & Networks
- Investors
SECTION 2 - RESEARCH METHODOLOGY
- About this Pulse Report
- Scope & Segmentation
- Marketstrat's "Insights -> Action" Approach
- Dual lens Architecture
- Top down Market Funnel (Europe)
- How it Works in the Model
- Bottom up Attach rate Flow (Europe)
- What we model for Each Country and Segment
- Evidence Confidence - Density vs Reliability (Europe)
- Regional Frameworks Included in this Pulse Report
- GTM Country Tools
- Quality Assurance & Governance
- Limitations & Mitigations
SECTION 3 - EUROPEAN MARKET ANALYSIS
- Market Overview & Analysis
- Market Snapshot
- Structural Demand Signals
- Regulatory & Funding Landscape (2024-2028)
- Market Segmentation 2032 (value share)
- Competitive Heat Map (2024-26)
- Execution Playbook (2024-2027)
- Action-Oriented Recommendations
- European Market Estimates and Forecasts by Country (2023-2032, USD Mill)
- Five Forces Shaping Adoption
- Country Archetypes & What Sells
- Near term Adoption Runway (2024-27)
- Strategic Implications
- Regulatory Velocity by Company - Europe
- Markintel Growth Maturity Matrix - Europe
- Landscape Snapshot
- Why the Quadrant Looks the Way it Does
- Key Competitive Dynamics
- Strategic Takeaways
- Bottom Line
- M&A Watchlist - Europe
- Competitive Dataset - Europe
- Growth & Maturity Highlights - Europe
- Markintel Ecosystem Collaboration Matrix (ECM) - Europe
- Quadrant Commentary & European Illustrations
- Action Checklist
- Markintel Solution Adoption & Growth Matrix - Europe
- Quadrant Deep Dive
- What Moves a Solution from One Box to the Next?
- Strategic Guidance
- AI Attach Rate - Europe
- OEM AI Attach Rate
- Attach Rate Trends - Europe
- AI Revenue Split - Factory vs Retrofit Attach -- Europe
- GTM at a Glance - Europe
- Channel & Pricing Matrix (2025-2028)
- GTM Readiness Radar - Europe
- Tiered Customer Landscape (2032 View)
- GTM Timeline (2025 -> 2028) - Europe
- Adjacency Opportunity Radar (2026+) - Europe
- Regulatory x Funding Heatmap - Europe
- AI Imaging Whitespace Matrix - Europe
- Fast Strategic Cues (2025 playbook)
SECTION 4 - GERMAN MARKET
- Market Overview - Germany
- Macro & Epidemiology
- Health system & Funding Landscape
- Regulatory & Evidence Pathway
- Competitive Landscape
- Strategic Takeaways & Recommendations
- German Market by Clinical Area
- Forecast by Clinical Area (2023-2032, USD Mill)
- Primary Growth Catalysts
- Strategic Messages for Stakeholders
- Key Takeaways
- German Market by Modality (2023-2032, USD Million)
- Forecast by Modality (2023-2032, USD Mill)
- Key Inflection by Modality
- What's Driving Each Modality
- Strategic Implications
- German Market by Revenue Stream (2023-2032, USD Million)
- Forecast by Revenue Stream (2023-2032, USD Mill)
- Revenue Streams and Drivers
- Key Dynamics by Stream
- Strategic Guidance
- German Market by Clinical Application (2023-2032, USD Million)
- Forecast by Clinical Application (2023-2032, USD Mill)
- What is Driving Each Bucket
- Strategic Messages
- Action Playbook
- German Market by End-Use Organization (2023-2032, USD Million)
- Forecast by End-Use Organization (2023-2032, USD Mill)
- Segments Review
- Strategic Implications
- German Market by AI Technology (2023-2032, USD Million)
- Forecast by AI Technology (2023-2032, USD Mill)
- Germany - AI Imaging Market by Core Technology
- Why Deep Learning Keeps the Lion's Share
- Break-out Growth Themes
- Strategic Playbook
- GTM at-a-Glance - Germany
- Channel x Pricing Matrix
- GTM Readiness Radar - Germany
- Tiered Customer Landscape
- GTM Timeline - Germany
- Fast Strategic Cues
SECTION 5 - FRENCH MARKET
- Market Summary: France
- Top line Snapshot - France
- Key Market Dynamics
- Strategic Takeaways
- Top 3 Recommendations
- French Market Speed scan - Market Analysis (2024-2032)
- French Market Estimates and Forecasts (2023-2032)
- French Market by Clinical Area (2023-2032)
- French Market by Modality (2023-2032)
- French Market by Revenue Stream (2023-2032)
- French Market by Clinical Application (2023-2032)
- French Market by End-Use Organization (2023-2032)
- French Market by AI Technology (2023-2032)
- GTM at a Glance - France
- Channel x Pricing Matrix
- GTM Readiness Radar - What Counts Most in France
- GTM Timeline (2024-30) - France
- Spend Potential by Customer Tier - France
SECTION 6 - UNITED KINGDOM MARKET
- Market Overview - United Kingdom
- UK Market Speed Scan
- Scale & growth
- Policy & funding
- Demand triggers
- Procurement routes
- Competitive Field
- Winning playbook 2024-27
- UK Market Estimates and Forecasts (2023-2032)
- UK Market by Clinical Area (2023-2032)
- UK Market by Modality (2023-2032)
- UK Market by Revenue Stream (2023-2032)
- UK Market by Clinical Application (2023-2032)
- UK Market by End-Use Organization (2023-2032)
- UK Market by AI Technology (2023-2032)
- GTM at a Glance - UK
- Channel x Pricing Matrix
- GTM Readiness Radar - UK
- Fast Strategic Cues
- Tiered Customer Landscape - UK
- GTM Timeline (2024-29) - UK
SECTION 7 - ITALIAN MARKET
- Market Overview & Summary: Italy
- What Makes Italy Unique in the EU Context
- Strategic Takeaways
- Italian Market Estimates & Forecasts (2023-2032)
- Italian Market by Clinical Area (2023-2032)
- Italian by Modality (2023-2032)
- Italian Market by Revenue Stream (2023-2032)
- Italian Market by Clinical Application (2023-2032)
- Italian Market by End-Use Organization (2023-2032)
- Italian Market by AI Technology (2023-2032)
- GTM at a Glance - Italy
- Channel x Pricing Matrix
- Tiered Customer Landscape & Spend Potential (2032) - Italy
- GTM Readiness Radar - Italy
- GTM Timeline (2024-29) - Italy
- Fast Strategic Cues
SECTION 8 - SPANISH MARKET
- Market Overview & Summary - Spain
- Strategic Takeaways
- Spanish Market Estimates and Forecasts (2023-2032)
- Spanish Market by Clinical Area (2023-2032)
- Spanish Market by Modality (2023-2032)
- Spanish Market by Clinical Application (2023-2032)
- Spanish Market by Revenue Stream (2023-2032)
- Spanish Market by End-Use Organization (2023-2032)
- Spanish Market by AI Technology (2023-2032)
- GTM at a Glance - Spain
- GTM Readiness Radar - Spain
- Channel x Pricing Matrix
- Tiered Customer Landscape - Spain
- GTM Timeline - Spain
SECTION 9 -REST OF EUROPE (ROE) MARKET
- Market Overview: Rest of Europe (ROE)
- Size & trajectory
- Why Growth Accelerates
- Risks / Headwinds
- Strategic Takeaways
- Rest of European Market for AI in Medical Imaging (2023-2032)
- Rest of European Market by Clinical Area (2023-2032)
- Rest of European Market by Modality (2023-2032)
- Rest of European Market by Revenue Stream (2023-2032)
- Rest of European Market by Clinical Application (2023-2032)
- Rest of European Market by End-Use Organization (2023-2032)
- Rest of European Market by AI Technology (2023-2032)
- GTM at a Glance - Rest of Europe (ROE)
- GTM Readiness Radar - ROE
- Tiered Customer Landscape - ROE
- GTM Timeline - ROE
- Channel x Pricing Matrix
- Adjacency-Opportunity Matrix (2026-2030)
- Country-Cluster Framework & Strategic Playbook
- White-Space Partnership Matrix
- Regulatory Funding Heatmap (ROE Clusters)
- Fast Strategic Cues